Drug Database
Back to search

Netherlands· NL-4969dda314c7

Epclusa 150 mg/37,5 mg, omhuld granulaat in sachet

A sofosbuvir and velpatasvir product containing sofosbuvir + velpatasvir, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 16 of our 19 countries.

ATC J05AP55

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEpclusa 150 mg/37,5 mg, omhuld granul…ATCJ05AP55REGISTER NO.NL-4969dda314c7PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sofosbuvir + velpatasvirAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sofosbuvir and velpatasvir is registered in 16 of 19 countries.

Countries holding a registration under ATC J05AP55 (sofosbuvir and velpatasvir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 11 of them publish a price we can compare per daily dose
Search sofosbuvir and velpatasvir products by name

Sofosbuvir and velpatasvir · ATC J05AP55

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
SOFOSBUVIR + VELPATASVIR
Manufacturer
Gilead Sciences Ireland UC
Country
Netherlands (NL)
ATC code
J05AP55
ATC class
Sofosbuvir and velpatasvir
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/16/1116

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

80 interactions on record for sofosbuvir and velpatasvir.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sofosbuvir and velpatasvir against other medicinesHow interaction checks work

Sofosbuvir and velpatasvir · interactions on record

80 records

  • 14 severe
  • 61 moderate
  • 5 minor

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sofosbuvir and velpatasvir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir and velpatasvir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Epclusa
  • Liechtenstein · Epclusa
  • Norway · Epclusa

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4950d432-dcbf-4a02-9df3-1477ff187cd9
GET /v1/drugs/4950d432-dcbf-4a02-9df3-1477ff187cd9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Omhuld granulaat",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Sofobuvir and velpatasvir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127989",
  "excipients": [
    "BASISCH GEBUTYLEERD METHACRYLAAT COPOLYMEER (E 1205)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOVIDON (E 1208)",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE (E 551)",
    "STEARINEZUUR (E 570)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "WIJNSTEENZUUR, (L (+) Vorm) (E 334)"
  ],
  "substances": [
    "SOFOSBUVIR",
    "VELPATASVIR"
  ],
  "leaflet_url": null,
  "authorised_at": "2016/07/06",
  "procedure_number": "EMEA/H/C/004210",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/16/1116",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about sofosbuvir and velpatasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console